PARP inhibitor talazoparib showed increased potency in HR-deficient pancreatic cancer compared to standard olaparib, promoting better treatment outcomes.
The study validated talazoparib's efficacy across various HR-deficient genotypes in patient-derived organoids and murine models for personalized medicine.
Combination therapy with DNA repair inhibitors was systematically tested, showing promising results in ATM, BRCA1, BRCA2, and PALB2 deficient cells.
The refined talazoparib-based regimen supports extending treatment options for a wider group of pancreatic cancer patients with HR deficiencies.